ADDED
The number of outstanding shares of common stock of the registrant, $0.00001 par value per share, as of February 26, 2026 was 73,749,607 .
Food and Drug Administration s (the FDA ) refusal to accept data from trials we or our strategic partners conduct outside the United States; disruptions at the FDA and other government agencies caused by funding shortages, global health concerns or changes implemented by the current U.S.
Consequently, forward-looking statements should be regarded solely as our current plans, estimates and beliefs.
Our registered trademarks include Azymetric, Zymeworks, ZymeCAD, EFECT, ZymeLink and ProTECT.
Business Overview Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat conditions, including cancer, inflammation, and autoimmune disease.
We believe our asset and royalty aggregation strategy differentiates us from other biotechnology companies because it provides us with an opportunity to optimize future milestone and royalty cash flows and selectively invest in high-quality assets while retaining the flexibility to return capital to stockholders.
Our Strategy Our strategy is focused on compounding long-term stockholder value through a combination of royalty growth, strategic acquisitions, and internal innovation, supported by disciplined capital allocation and a strengthened financial foundation through expected milestone payments and royalties from existing commercial partners.
We pursue this strategy by discovering or acquiring and developing a diversified portfolio of preclinical or clinical healthcare assets while also evaluating strategic partnership opportunities to transfer certain costs and risks related to clinical development a nd/or commercialization to our strategic partners and secure the right to receive potential future royalty and milestone revenues.
The following elements collectively support the execution of our strategy.
Proprietary Technology Platforms and R D Engine We seek to leverage our expertise in protein engineering and drug chemistry to discover and develop next-generation antibody-based therapeutics to address significant unmet medical needs, particularly in hard-to-treat diseases.
REMOVED
The number of outstanding shares of common stock of the registrant, $0.00001 par value per share, as of March 3, 2025 was 69,576,883 .
In particular, these forward-looking statements include, but are not limited to, statements about: the size of our addressable markets and our ability to commercialize product candidates; the achievement of advances in and expansion of our therapeutic platforms and antibody engineering expertise; the likelihood of product candidate development and clinical trial progression, initiation or success; and our ability to predict and manage government regulation.
Our registered trademarks include Azymetric, Zymeworks, ZymeCAD, EFECT, ZymeLink and the phrase Building Better Biologics .
Unless the context otherwise requires or otherwise expressly states, all references in this Annual Report on Form 10-K to Zymeworks, the Company, we, us and our (i) for periods until the Redomicile Transactions, refer to Zymeworks BC Inc.
and its subsidiaries and (ii) for periods after the Redomicile Transactions, refer to Zymeworks Inc.
Business Overview Zymeworks is a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases ( AIID ).
Zymeworks complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates from preclinical candidate screening through to registrational clinical trials.
We believe our strategic development priorities position us as thought leaders in our therapeutic areas of interest, driven by a patient-centric approach, scientific innovation, and operational excellence.
Our research and development strategy centers on three key pillars: Target Selection: Our data-driven target strategy is informed by target expression, target biology (including internalization rate), tumor biology, clinical precedence and differentiation to prior therapeutic programs.
For example, mesothelin ( MSLN ), folate receptor- ( FR ) and sodium-dependent phosphate transporter 2b ( NaPi2b ) are each expressed at higher levels than other targets pursued in ovarian cancer or non-small cell lung cancer ( NSCLC ).